Lemborexant
Search documents
Eisai Co., Ltd. - Lemborexant and Novel Orexin Receptor Agonist E2086 World Sleep 2025
Seeking Alpha· 2025-09-11 08:55
PresentationUnknown Executive Thank you very much for taking your time. We would now like to begin oral presentation of highlight of E2086 from World Sleep 2025 oral presentation. This is a virtual session. Please check our website for presentation material. In Singapore this week, World Sleep 2025 was held. E2086 Phase I study results were presented in oral presentation. The highlight of the presentation will be given today, and questions will also be taken to deepen understanding of the audience of E2086. ...
Eisai Co., Ltd. (ESAIY) Discusses On Latest Data On Lemborexant And Novel Orexin Receptor Agonist E2086 At The World Sleep 2025 Transcript
Seeking Alpha· 2025-09-11 08:55
Core Insights - The World Sleep 2025 conference took place in Singapore, where the Phase I study results of E2086 were presented [2] - Dr. Katsutoshi Ido, the Chief Scientific Officer, led the presentation and addressed audience questions to enhance understanding of E2086 [2] Group 1 - The presentation of E2086's Phase I study results was a highlight of the World Sleep 2025 event [2] - The session was conducted virtually, and additional presentation materials are available on the company's website [1]